Lv4
486 积分 2025-10-25 加入
Hepatic inflammatory responses in liver fibrosis
1小时前
待确认
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes
1个月前
已完结
Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons
1个月前
已完结
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States
1个月前
已完结
Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study
1个月前
已完结
The impact of chiglitazar, a pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: a real-world study
1个月前
已完结
The impact of chiglitazar, a pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: a real-world study
1个月前
已完结
Chiglitazar attenuates high-fat diet-induced nonalcoholic fatty liver disease by modulating multiple pathways in mice
1个月前
已完结
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
1个月前
已完结
Dual inhibition of hepatic ACLY and ACSS2: a synergistic approach to combat NAFLD through lipogenesis reduction and mitochondrial enhancement
1个月前
已完结
皖公网安备34019202002308
